Clinical Trials Directory

Trials / Completed

CompletedNCT00190320

DAME: Induction of Labor or Waiting for Suspicion Fetal Macrosomia

Induction of Labor or Waiting for Suspicion Fetal Macrosomia (DAME)

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
1,000 (actual)
Sponsor
Assistance Publique - Hôpitaux de Paris · Academic / Other
Sex
Female
Age
18 Years – 48 Years
Healthy volunteers
Not accepted

Summary

Aim of the study :The major aim is to evaluate the effectiveness of the induction of labor in case of fetal macrosomia on the reduction of neonatal traumatism risk. The secondary aims are to evaluate maternal morbidity and the risk of Caesarean in case of induction of labor, compared to a spontaneous labor.

Detailed description

A clinical trial multicentric randomized controlled will be organized. A total of 1000 women will be recruited between 36 and 38 weeks of amenorrhoea (GW) if the pregnancy is single, in cephalic presentation and the fetus is estimated macrosomic for the gestational age (\> 90e percentile clinically and \>95° percentile sonographically).All agreeing patients will be randomized in one of the two following groups: - 1. Induction of labor between 37+0 and 38+6 GW and within 3 day after the randomization. - 2. Expectancy until the spontaneous beginning of labor or up to 41 GW.The measurement of principal exit is the neonatal traumatism (criterion composite associating: dystocia of the shoulders, fractures osseous, paralysis/paresis of the plexus brachial or intracerebral haemorrhage).The secondary criteria are neonatal asphyxiation (arterial pH \< 7.10 or Apgar \< 7 to 5 minutes), the maternal traumatism (tear of 3rd or 4th degree) and the Caesarean. The long-term after-effects for the mother and her child will be also evaluated

Conditions

Interventions

TypeNameDescription
PROCEDUREInduction of labor vs waiting

Timeline

Start date
2005-02-01
Primary completion
2009-02-01
Completion
2009-02-01
First posted
2005-09-19
Last updated
2011-02-17

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT00190320. Inclusion in this directory is not an endorsement.